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Abstract
Background: Obesity hypoventilation syndrome (OHS) is associated with increased cardiovascular morbidity. What
moderate chronic hypoventilation adds to obesity on systemic inflammation and endothelial dysfunction remains unknown.
Question: To compare inflammatory status and endothelial function in OHS versus eucapnic obese patients.
Methodology: 14 OHS and 39 eucapnic obese patients matched for BMI and age were compared. Diurnal blood gazes,
overnight polysomnography and endothelial function, measured by reactive hyperemia peripheral arterial tonometry (RH-
PAT), were assessed. Inflammatory (Leptin, RANTES, MCP-1, IL-6, IL-8, TNFa, Resistin) and anti-inflammatory (adiponectin, IL-
1Ra) cytokines were measured by multiplex beads immunoassays.
Principal Findings: OHS exhibited a higher PaCO2, a lower forced vital capacity (FVC) and tended to have a lower PaO2 than
eucapnic obese patients. HS-CRP, RANTES levels and glycated haemoglobin (HbA1c) were significantly increased in OHS
(respectively 11.1610.9 vs. 5.765.5 mg.l
21 for HS-CRP, 55.9655.3 vs 23.3615.8 ng/ml for RANTES and 7.364.3 vs 6.161.7 for
HbA1c). Serum adiponectin was reduced in OHS (760662977 vs 1366067854 ng/ml). Endothelial function was significantly
more impaired in OHS (RH-PAT index: 0.2260.06 vs 0.5160.11).
Conclusions: Compared to eucapnic obesity, OHS is associated with a specific increase in the pro-atherosclerotic RANTES
chemokine,adecrease in the anti-inflammatoryadipokine adiponectin andimpaired endothelial function.Thesethree conditions
are known to be strongly associated with an increased cardiovascular risk.
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Introduction
The obesity-hypoventilation syndrome (OHS) is defined by
obesity (BMI$30 kg/m
2), and chronic alveolar hypoventilation
resulting in daytime hypercapnia (PaCO2.45 mmHg), after
exclusion of all other causes of alveolar hypoventilation (severe
obstructive or restrictive diseases, chest wall disorders, neuromus-
cular diseases)[1–3]. Patients suffering from OHS are considered to
be more severely affected compared to eucapnic obese patients. The
use of health-care resources is increased compared to usual obese
patients [4] and OHS is carrying a momentous cardiovascular
morbidity [2,5]. Compared with obese control subjects, patients
with OHS are statistically much more likely to have been diagnosed
with congestive heart failure (OR 9; 95% CI, 2.3–35), angina
pectoris (OR, 9; 95% CI, 1.4–57.1)and cor pulmonale (OR, 9; 95%
CI,1.4–57.1)[4].Inobese,prospectivelyfollowedduring18months
after hospital discharge, OHS patients had a higher rate of death
compared to simple obesity (23% versus 9%) [6].
Obesity is a disease state characterized by chronic systemic low
grade inflammation and associated inflammatory changes in the
adipose tissue [7–10]. OHS adds up on obesity several extra stimuli
that might increase the burden of chronic inflammation and as a
consequence its proatherogenic effects. Work of breathing is higher in
OHS compared to eucapnic obesity [11]. It has been demonstrated
that adding a load to the respiratory system is resulting in
proinflammatory cytokines release [12,13]. Up to 85% percent of
OHS patients are exhibiting sleep apnea, a disease condition, linked
with cardiovascular diseases [14]. Furthermore, OHS is character-
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oxygen desaturations during REM sleep and concomitant repeated
acute increases in PaCO2. In animal models and humans, hypoxia of
the adipose tissue has been shown to be associated with local fat
inflammation[15,16]. Thus, an aggravation in adipose tissues of
inflammatory state is conceivable in OHS. Finally, the pivotal
mechanism underlying daytime hypercapnia in OHS is the reduction
in ventilatory drive owing to central leptin resistance [17,18]. Central
leptin resistance results in high plasmatic levels of leptin and
preservation of peripheral actions of leptin such as increased
sympathetic outflow and cytokine production [19].
Thus, it seemed reasonable to hypothesize that OHS compared
to eucapnic obesity could be associated with increased systemic
inflammation and with an increased production of proinflamma-
tory adipocytokines. Furthermore Apovian et al. have recently
demonstrated that local adipose tissue inflammation is linked with
endothelial dysfunction [7]. We postulated that OHS patients
would exhibit a specific inflammatory response and a more severe




Obesity hypoventilation syndrome (OHS) was defined by a body
mass index (BMI) above 30 kg/m
2 and a PaCO2.6k P ao nd a y t i m e
blood gazes, without any significant airway obstruction (FEV1/
FVC,70%), history of heart failure or progressive neuromuscular
disease. OHS patients were compared to control subjects (eucapnic
obesity group), in a case control study design. Both groups of subjects
came from an obese database of subjects recruited by advertisement in
newspapers or addressed to the sleep laboratory for suspicion of
obstructive sleep apnea syndrome (OSAS). Among 104 obese in the
database at the time of the analysis, each OHS patient was matched
with up to 6 eucapnic obese. Patients were matched for two classes of





All the patients underwent a baseline screening visit including sleep
studies, respiratory assessment and cardiovascular function before been
potentially involved in a randomized interventional controlled study.
After this baseline visit, only those subjects having obesity hypoven-
tilation syndrome were randomized in a one month comparison
between non invasive ventilation and standard care. This randomized
controlled study is ongoing [clinical trial registration number:
NCT00603096]. The current study is reporting the results of a case
control comparison of two clusters of obese exhibiting or not OHS and
matched for age and BMI.
The study was approved by the university hospital ethics
committee. All patients signed a written informed consent.
Study design
Patients underwent an overnight polysomnography. After
waking up, in fasting state, a peripheral blood sample was drawn
and endothelial dysfunction was assessed by reactive hyperhemia
with finger plethysmographic methodology (RH-PAT). After
breakfast, Epworth sleepiness scale, pulmonary function tests,
arterial blood gases analysis, and ventilatory response to CO2 were
performed.
Study procedures
Polysomnography (PSG). An overnight PSG was performed
during spontaneous breathing in order to characterize abnormal
respiratory events during sleep according to standard criteria
[20,21] as previously described [22,23].
Biomarkers. After peripheral blood sampling, plasma
glucose and serum triglycerides levels were measured on
automat (Modular 700, Roche, Meylan, France). Serum insulin
was measured using a radio-immunometric sandwich assay (CIS
bio international, Gif-Sur-Yvette, France). Serum HS-CRP level
was measured using automated immunonephelometry (Behring
Nephelometer II Analyzer, Dade Behring, Germany).
Leptin, CCL5/RANTES (Regulated upon activation normal T-
cell express an secreted), CCL2/MCP1 (Monocyte chemo-
attractant protein 1), IL-6, IL-8, TNFa, Resistin, Adiponectin
and IL-1Ra were measured by commercially available multiplex
beads immunoassays (Fluorokine MAP Multiplex Human Cyto-
kine Panel and Obesity Panel, R&D Systems, Minneapolis, USA)
and read by the Bioplex 200 array reader (Bio-Rad Laboratories,
Hercules, CA, U.S.A.) which uses Luminex xMAP
TM Technology
(Luminex Corporation, Austin, TX, U.S.A.).
Respiratory function and ventilatory responses to
CO2. Spirometry and plethysmography were measured accor-
ding to the European Respiratory Society recommendations [24].
CO2 chemo-sensitivity was assessed using Read’s method [25].
Endothelial Dysfunction. Endothelial dysfunction was
assessed by reactive hyperhemia with finger plethysmographic
methodology (RH-PAT, i.e Reactive Hyperhemia Peripheral
Arterial Tonometry) using Endo-PAT device (Itamar Medical
Ltd, Caesarea, Israel) as previously described [26,27]. RH-PAT
index was calculated as the natural logarithm of the average
amplitude of PAT signal after 90 to 120 second deflation divided
by average amplitude of the PAT signal during 210 second prior
the cuff inflation [28].
Statistical analysis
Our main objective was to unmask differences in endothelial
dysfunction between OHS and eucapnic obese patients matched
for age and BMI. Our secondary goal was to assess inflammatory
parameters differences between the two groups. The first step was
to use univariate conditional logistic regression to compare the two
groups. Then, multivariate conditional logistic regression models
were used to examine the effects of potential confounders other
than those controlled for by matching, including parameters
unbalanced between groups. For all the tests, a significant level of
p,0.05 was used. SAS 9.1.3 package (SAS Institute, Cary, NC,




Fourteen obesity hypoventilation syndrome patients (OHS) were
compared to 39 ‘‘eucapnic obese’’ matched for age and BMI. By
definition, PaCO2 was more elevated in OHS than in obese group
(6.4560.39 vs 5.3160.44 kPa). PaO2 tend to be lower (9.7861.73
vs 10.7161.44 kPa). Anthropometrics, blood pressure and lung
function characteristics are reported in Table 1. Sex ratio was not
different between the two groups. OHS had significantly impaired
lung volumes. Compared to eucapnic obese (Table 2), OHS had
comparable severity in obstructive sleep apnea syndrome as
expressed by apnea+hypopnea index (AHI=40628 for UO vs.
57654 for OHS). Three OHS patients had AHI#5/h compared to
two patients in the eucapnic obese group. OHS spent more time
during sleep with oxygen saturation (SpO2) less than 90% and had
lower nadir nocturnal SpO2. As shown in table 3, OHS had higher
glycated hemoglobin and tended to be more frequently treated for
hypertension. HOMA index reflecting insulin resistance was three
time higher in OHS than in eucapnic obese.
Endothelial Dysfunction in OHS
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HS-CRP was significantly elevated in OHS compared to
eucapnic obese (mean6SD: 11.1610.9 vs. 5.765.5 mg.l
21,
p,0.05). Serum level of RANTES, a pro-atherosclerotic chemo-
kine, was also significantly increased in OHS (55.9655.3 vs
23.3615.8 ng/ml, p=0.04) (table 4). Others pro-inflammatory
cytokines, chemokines except MCP1, were not different between
the two groups. Adiponectin, an anti-inflammatory adipokine was
significantly lowered in OHS compared to UO (760662977 vs
1366067854, ng/ml p=0.025). (table 4).
Endothelial dysfunction
Endothelial function was significantly more impaired in OHS
patients than in UO patients (RH-PAT index: 0.2260.06 versus
0.5160.11 respectively, odds ratio=0.02 [0.01–0.48) p=0.03].
Figure 1 depicts parameters which differed between OHS and
eucapnic obsese patients in univariate analysis. In a multivariate
analysis, after adjustment for potential confounders (i.e: FVC,
Sleep time spent with SpO2,90%, HbA1c), neither RANTES,
nor adiponectin and RH-PAT were independently associated with
the risk of having OHS.
Discussion
In this prospective controlled study, we compared for the first
time inflammatory status and endothelial function in obesity
hypoventilation syndrome and eucapnic obesity. We observed that
the proatherogenic chemokine RANTES (CCL5) increased
significantly whereas insulin sensitizing and antiatherogenic
adipokine adiponectin was significantly reduced in OHS patients.
Consistently, endothelial function was significantly more impaired
in obesity hypoventilation syndrome than in eucapnic obesity.
Not only obesity but many other systemic diseases like diabetes,
COPD, cardiovascular diseases or sleep apnea are associated with
an underlying pro-inflammatory state [8,29,30]. Although sharing
what is generally called ‘low-grade’ or ‘chronic’ inflammation, all
these diseases present different time course evolution and
prognosis. Moreover, obesity per se, is not a homogeneous
condition. It would be useful to distinguish subclasses of
inflammation among obese populations reflecting different risks
and allowing tailoring specific anti-inflammatory treatments. The
present study is the first to compare the serum profile of an
extensive panel of 9 chemokines and adipokines by multiplex assay
in OHS and eucapnic obese patients. Of all chemokines tested,
Table 1. Anthropometric characteristics and respiratory function.
OHS (14) Eucapnic Obese (39) Odds Ratio (95% CI)
Sex F/M 9/5 26/13 0.83 (0.24–2.81)
Age (years) 57610 56610 0.99 (0.90–1.09)
BMI (kg/m
2) 41.065.2 40.965.1 1.02 (0.85–1.23)
Waist/Hip ratio 0.9860.06 0.9460.1 1.52 (0.32–7.15)
Clinical SBP (mmHg) 133623 132612 1.00 (0.96–1.05)
Clinical DBP (mmHg) 75698 0 610 0.96 (0.90–1.02)
FVC (% predicted value) 72624 92617 ** 0.93 (0.89–0.98)
TLC (% predicted value) 90617 99612
1 0.95 (0.90–1.00)
FEV1/FVC (%) 84687 9 68 0.11 (0.97–1.28)
CO2 sensitivity (l/min/mmHg) 1.460.9 2.461.5
1 0.51 (0.25–1.06)
OHS: Obesity hypoventilation syndrome; BMI: Body Mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FVC: forced vital capacity, expressed as
percentage of predicted value; TLC: total lung capacity as percentage of predicted value; FEV1/FVC: forced expiratory volume in 1 second on forced vital capacity ratio;
CO2 sensitivity: Central CO2 chemo-sensitivity was assessed using Read’s method [25]. Results are expressed as mean6SD.
1:p ,0.1; *: p,0.05 **: p,0.01 using univariate conditional logistic regression.
doi:10.1371/journal.pone.0006733.t001
Table 2. Sleep structure and sleep associated disorders breathing.
OHS (14) Eucapnic Obese (39) Odds Ratio (95% CI)
Total Sleep Time (min) 341666 338683 1.00 (0.99–1.01)
Sleep 1–2 (% of total sleep time) 75697 2 610 1.05 (0.95–1.15)
Sleep 3–4 (% of total sleep time) 5687 68 0.98 (0.87–1.10)
REM Sleep (% of total sleep time) 19672 1 68 0.96 (0.87–1.06)
AHI (n/h) 57654 40628 1.01 (0.99–1.03)
Respiratory-related m-arousals(n/h) 50636 36620 1.02 (0.99–1.04)
Mean nocturnal SpO2 (%) 89659 1 64 0.90 (0.78–1.03)
Nadir nocturnal SpO2 (%) 65615 76610 * 0.94 (0.89–0.99)
Sleep time spent with SpO2,90% (%) 44635 19621 * 1.04 (1.01–1.08)
REM: Rapid eye movement sleep; AHI: Apnea-hypopnea index; SpO2: oxygen saturation Results are expressed as mean6SD.
1:p ,0.1; *: p,0.05 using univariate conditional logistic regression.
doi:10.1371/journal.pone.0006733.t002
Endothelial Dysfunction in OHS
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chemokine that has been involved in atherogenesis [31], and that
is also related to coronary heart disease risk in middle age subjects
[32]. Circulating RANTES level is elevated in symptomatic
coronary artery disease [33] and is also acutely increased in
unstable angina pectoris during severe ischemic symptoms [34].
RANTES is expressed by activated platelets, lymphocytes and
adipocytes [35,36]. As a result circulating RANTES concentra-
tions are elevated in obese rats [37], during human obesity,
impaired glucose tolerance and type 2 diabetes [38]. The design of
the present study did not allow identifying the main source of
plasmatic RANTES but we can speculate on a predominant
visceral fat and/or activated platelets origin for RANTES. Indeed,
Hosegai et al. [15] have shown that local adipose tissue hypoxia in
mice dysregulates adipokines production. In the present study,
OHS patients exhibited more severe daytime hypoxaemia and
nocturnal oxygen desaturations compared to matched eucapnic
obese. Thus, mild hypoxaemia during daytime and severe
desaturation during sleep, the later representing an additional
hypoxic insult, might favor RANTES production by adipose
tissue. On the other hand, thromboembolism is 4 fold increased in
mortality in OHS compared to eucapnic obesity [6], suggesting a
pro-coagulant state in OHS potentially linked to platelet
activation. Platelets are the main source of RANTES and the
interplay between RANTES and platelets allow monocytes arrest,
a determinant pathway in atherosclerosis initiation [36]. Further
studies directly addressing local fat inflammation and platelets
activation in the specific population of OHS are required to
elucidate the respective contribution of these two pathways in
RANTES up-regulation.
Whereas proatherogenic RANTES increased significantly,
insulin sensitizing and antiatherogenic adipokine adiponectin
was significantly reduced in our OHS patients. Obesity-related
cardiovascular diseases are associated with decreased plasma levels
of adiponectin [39,40]. Hypoadiponectinemia correlates signifi-
cantly and independently with coronary artery disease [41] and
more generally plasma adiponectin levels are an inverse predictor
of cardiovascular outcome [39]. In our study, as for RANTES, the
severity of sleep apnea and REM sleep related desaturations
together with moderate daytime hypoxaemia, may play a major
role as it has been demonstrated that local hypoxia at the
abdominal fat level reduced adiponectin release by the adipocytes
[15]. In the present study, we evidenced for the first time that
hypoadiponectinemia is further reduced in OHS compared to non
OHS obese subjects. This result is in accordance with the OHS
observational cohorts data, demonstrating a higher prevalence of
cardiovascular diseases as well as increased mortality of OHS
patients [2,6]. We also found that OHS patients tend to used more
antihypertensive agents had higher insulin resistance and were
more frequently treated by glucose lowering medications.
However, strong evidence base medicine is lacking in this field
and epidemiological studies in different subclasses of obesity are
desirable to more clearly delineate the respective metabolic and
cardiovascular risk of different subgroups of obese subjects with
and without daytime hypoventilation [42].
As we have demonstrated a specific pattern of inflammation and
a decrease in adiponectin levels, we also observed an aggravated
endothelial dysfunction in OHS patients [43]. This is supporting a
particular cardiovascular risk associated with OHS as endothelial
dysfunction is an early key event of atherosclerosis and a strong
Table 3. Cardiovascular, metabolic status and history.
OHS (14) Eucapnic Obese (39) Odds Ratio (95% CI)
Treated hypertension , % 86 54
1 4.74 (0.85–26.53)
Diabetes, % (Treated for diabetes, %) 54 (43) 29 (21) 3.00 (0.80–11.34)
Statins, % 43 23 1.89 (0.50–7.09)
Fast blood insulin level, mu.mL
21 22.7621.1 11.267.9
1 1.06 (0.99–1.12)
Fast blood glucose level mmol/l 7.563.8 6.562.7 1.15 (0.90–1.48)
HOMA – IR (G*I/22.5) 9.8613.0 3.262.4
1 1.14 (0.98–1.33)
HbA1c, % 7.364.3 6.161.7 * 8.76 (1.02–75.00)
Triglycerids, g/l 1.6960.8 1.460.7 1.75 (0.70–4.40)
HDL cholesterol, g/l 0.4160.13 0.4060.1 1.51 (0.40–5.72)
LDL cholesterol, g/l 1.060.4 1.360.5
1 0.23 (0.05–1.09)
Total Cholesterol, g/l 1.860.5 2.060.6 0.34 (0.08–1.39)
HOMA-IR was calculated with the formula: Fast blood glucose level*Fast blood insulin level/22.5; HbA1c: Glycated haemoglobin; HDL: High density lipoprotein; LDL:
Low density lipoprotein. Results are expressed as mean6SD. 6SD.
1:p ,0.1; *: p,0.05 using univariate conditional logistic regression.
doi:10.1371/journal.pone.0006733.t003
Table 4. Serum levels of 9 cytokines in Obesity
Hypoventilation Syndromes (OHS) compared to






IL1-Ra, ng/ml 1.661.4 1.761.9 1.00 (0.99–1.01)
MCP1, pg/ml 172672 216676* 0.98 (0.97–0.99)
IL8, pg/ml 6.863.4 18 .8645.3 1 0.88 (0.75–1.02)
TNFa, pg/ml 2.862.2 2.761.2 1.04 (0.68–1.58)
LEPTIN, ng/ml 92.5659.2 110.4682.5 0.99 (0.98–1.01)
IL6, pg/ml- 1.961.1 1.761.0 1.78 (0.80–3.93)
RESISTIN, ng/ml 6.862.8 7.164.7 0.96 (0.82–1.13)
RANTES, , ng/ml 55.9655.3 23.3615.8 * 1.03 (1.02–1.06)
ADIPONECTIN, ng/ml 760662977 1366067854* 0.15 (0.03–0.70)
1:p ,0.1; *: p,0.05, using univariate conditional logistic regression.
doi:10.1371/journal.pone.0006733.t004
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[42] have recently suggested that endothelial dysfunction aggra-
vates with increased degree of obesity, being more severe in super
obese (.50 kg/m
2) than in morbidly obese (.40 kg/m
2). They
assumed that more visceral fat in super obese patients can be an
explanation for their results. As the expected prevalence of OHS is
more than 50% in super obese patients versus only 30% in
morbidly obese [6], we suggest that OHS-induced inflammation
may be a complementary explanation. This is leading to propose a
systematic measurement of blood gazes both in clinical practice
and in research protocols in obese. In our study, even supra
normal values of PaCO2 were significantly linked with RANTES
elevation and endothelial dysfunction.
Conditional multivariate analysis did not allow to demonstrate
that endothelial dysfunction (i.e: RH-PAT) as well as inflammatory
status (i.e: high levels of RANTES/low levels of ADIPONECTIN-
MCP1) were independently associated with OHS. Actually,
hypoxia both sustained (morbid obesity) and/or intermittent
(OSAS) is acknowledged as triggering inflammatory pathways
mediated by the transcription factor nuclear factor kappa B (NF-
kB) and hypoxia-inducible factor 1 (HIF-1). Particularly, NF-kB is
a key player in inflammatory and innate immune responses.
Circulatory proinflammatory cytokines are then increased and at
the end these inflammatory processes directly induce endothelial
dysfunction[47,48]. Moreover, there is a close relationship
between insulin resistance, known to be associated with low serum
adiponectin level [49] and endothelial dysfunction[50]. Thus, it
appears that inflammatory cytokines, nocturnal desaturation,
glycated haemoglobin and endothelial dysfunction form a vicious
cycle where each results in worsening of the other.
Limitations of the study
Several limitations of this study need to be pointed out. Firstly,
the sample size of the study (n=53) is relatively limited. However,
in quality assessment before including the studies in the
metaanalysis of predicting factors to having OHS, Kaw et al.
keep prospective studies with case-control design including at least
10 patients with hypercapnia [1]. Our study corresponds to these
criteria. Secondly, owing to the sample size, boundaries for classes
of matching criteria were relatively wide. However, the sub-classes
of BMI used in the study are corresponding to the classical
definitions for moderate to morbid obesity [51].
Clinical implications, research and therapeutic
perspectives
Our study demonstrated that obesity hypoventilation syndrome
is a specific cluster in obesity associated with specific inflammation
and aggravated endothelial dysfunction. Whether RANTES
Figure 1. Comparison between Obesity Hypoventilation Syndrome (OHS) compared to eucapnic obese patients in RH-PAT, Sleep
time spent with SpO2,90%, FVC (% predicted value), glycated haemoglobin, serum levels of RANTES, Adiponectin and MCP1. TST:
total sleep time.
doi:10.1371/journal.pone.0006733.g001
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in this particular subgroup of obese needs to be addressed in future
studies [37,52]. However, this already have clinical implications as
individuals with elevated RANTES levels have higher risk to
develop diabetes mellitus despite intensive lifestyle intervention
than individuals with lower RANTES levels [53]. Moreover, non
invasive ventilation the current first line therapy of OHS should
now be evaluated, in randomized controlled trials, not only
regarding its effects on PaCO2, sleep and quality of life but also for
its cardiovascular and metabolic impact.
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